A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 24 May 2016
Price : $35 *
At a glance
- Drugs BAN 2401 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Eisai Inc
- 09 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Jan 2015 Planned End Date changed from 1 Feb 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
- 25 Jan 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.